| abstract |
One aspect of this description generally refers to lipid compounds that exert various effects on the endocannabinoid system, such as the regulation of the CB1 and CB2 receptor or the moderation of other bio-macromolecules within the endocanabinoid system; some of the compounds showed improved affinity of receptor binding, and / or improved selectivity of the receptor subtype, and improved bio-stability; Some of the compounds have activities to regulate enzymes that moderate the bio-elimination of endogenous cannabinoids, such as fatty acid amide hydrolase (FAAH); some of the compounds exhibit activities to inhibit the anandamide transporter; Other aspects of the invention are pharmaceutical preparations that employ these ligands and methods to administer therapeutically effective amounts of the preparations to provide a physiological effect. |